| Methods |
4‐week washout; no single‐blind placebo run‐in; inclusion criteria= mean sitting BP =/> 160/95 mm Hg and < 220/115 mm Hg after washout; 6‐week double‐blind treatment |
| Participants |
Valsartan 80 mg: n=20(13 males,7 females); mean age=52(9) years; baseline sitting SBP=171(9) mm Hg, DBP=102(3) mm Hg, HR=70.6(8.3) bpm;
Placebo: n=20(8 males,12 females); mean age=52(9) years; baseline sitting SBP=174(8) mm Hg, DBP=102(3) mm Hg, HR=70.3(6.8) bpm |
| Interventions |
Valsartan 80 mg once daily;
Placebo;
taken in the morning |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP |
| Notes |
BP change and SD of change reported, endpoint BP and SD not reported; BP data from text, p. 2425; BP measurement device not reported; Jadad score=2; funding source= Novartis Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
